Rocconi RP - Search Results

1

Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.

Rocconi RP, Monk BJ, Walter A, Herzog TJ, Galanis E, Manning L, Bognar E, Wallraven G, Stanbery L, Aaron P, Senzer N, Coleman RL, Nemunaitis J. Rocconi RP, et al. Gynecol Oncol. 2021 Jun;161(3):676-680. doi: 10.1016/j.ygyno.2021.03.009. Epub 2021 Mar 11. Gynecol Oncol. 2021. PMID: 33715892 Clinical Trial.

2

The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma.

Numnum TM, Rocconi RP, Whitworth J, Barnes MN. Numnum TM, et al. Among authors: rocconi rp. Gynecol Oncol. 2006 Sep;102(3):425-8. doi: 10.1016/j.ygyno.2006.05.018. Epub 2006 Jun 23. Gynecol Oncol. 2006. PMID: 16797681

3

Icodextrin enhances survival in an intraperitoneal ovarian cancer murine model utilizing gene therapy.

Rocconi RP, Numnum MT, Zhu ZB, Lu B, Wang M, Rivera AA, Stoff-Khalili M, Alvarez RD, Curiel DT, Makhija S. Rocconi RP, et al. Gynecol Oncol. 2006 Dec;103(3):985-9. doi: 10.1016/j.ygyno.2006.06.005. Epub 2006 Jul 20. Gynecol Oncol. 2006. PMID: 16857247

4

Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd).

Rocconi RP, Zhu ZB, Stoff-Khalili M, Rivera AA, Lu B, Wang M, Alvarez RD, Curiel DT, Makhija SK. Rocconi RP, et al. Gynecol Oncol. 2007 Apr;105(1):113-21. doi: 10.1016/j.ygyno.2006.10.057. Epub 2006 Dec 14. Gynecol Oncol. 2007. PMID: 17173958

5

A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer.

Moore KN, Herzog TJ, Lewin S, Giuntoli RL, Armstrong DK, Rocconi RP, Spannuth WA, Gold MA. Moore KN, et al. Among authors: rocconi rp. Gynecol Oncol. 2007 May;105(2):299-303. doi: 10.1016/j.ygyno.2006.12.031. Epub 2007 Feb 14. Gynecol Oncol. 2007. PMID: 17303230

6

Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients.

Rocconi RP, Matthews KS, Kemper MK, Hoskins KE, Barnes MN. Rocconi RP, et al. Gynecol Oncol. 2008 Feb;108(2):336-41. doi: 10.1016/j.ygyno.2007.10.012. Epub 2007 Nov 19. Gynecol Oncol. 2008. PMID: 18006047

7

The effect of obesity on survival in patients with ovarian cancer.

Matthews KS, Straughn JM Jr, Kemper MK, Hoskins KE, Wang W, Rocconi RP. Matthews KS, et al. Among authors: rocconi rp. Gynecol Oncol. 2009 Feb;112(2):389-93. doi: 10.1016/j.ygyno.2008.10.016. Epub 2008 Dec 5. Gynecol Oncol. 2009. PMID: 19062080

8

The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.

Rocconi RP, Matthews KS, Kemper MK, Hoskins KE, Huh WK, Straughn JM Jr. Rocconi RP, et al. Gynecol Oncol. 2009 Aug;114(2):242-5. doi: 10.1016/j.ygyno.2009.04.019. Epub 2009 May 17. Gynecol Oncol. 2009. PMID: 19447480

9

Targeted inhibition of telomerase activity combined with chemotherapy demonstrates synergy in eliminating ovarian cancer spheroid-forming cells.

Meng E, Taylor B, Ray A, Shevde LA, Rocconi RP. Meng E, et al. Among authors: rocconi rp. Gynecol Oncol. 2012 Mar;124(3):598-605. doi: 10.1016/j.ygyno.2011.11.018. Epub 2011 Nov 22. Gynecol Oncol. 2012. PMID: 22115853

10

The trend towards minimally invasive surgery (MIS) for endometrial cancer: an ACS-NSQIP evaluation of surgical outcomes.

Scalici J, Laughlin BB, Finan MA, Wang B, Rocconi RP. Scalici J, et al. Among authors: rocconi rp. Gynecol Oncol. 2015 Mar;136(3):512-5. doi: 10.1016/j.ygyno.2014.11.014. Epub 2014 Nov 20. Gynecol Oncol. 2015. PMID: 25462206

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

114 results

Search Page